- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03760445
HDM201 Added to CT in R/R or Newly Diagnosed AML
A Phase I/II Multi-center Study of HDM201 Added to Chemotherapy in Adult Subjects With Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)
Study Overview
Status
Conditions
Detailed Description
Study Type
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All Subjects
- Signed informed consent must be obtained prior to participation in the study
- Age ≥18
- Diagnosis of AML based on WHO 2016 classification. Patients with APL (acute promyelocytic leukemia) with PML-RARA are not eligible.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) that is 0 - 2.
- Adequate organ functions
- Left ventricular ejection fraction > 45%
For 1L AML population:
- For Part 1 or Part 2 Expansion Cohorts 1 or 2: subjects with de novo AML suitable for induction treatment with cytarabine and anthracyclines as per investigator judgement
- For Part 2 Expansion Cohort 2: documented presence of FLT3 mutation (ITD or TKD ) and suitable for midostaurin treatment as per investigator judgement.
- For Part 2 Expansion Cohort 3: Subjects with secondary AML (e.g. AML-MRC , secondary to myelodysplasia/MDS or therapy-related AML). Prior use of hypomethylating agents or other therapies with curative intent for treatment previous hematological malignancies or therapy-related AML is allowed. Subjects suitable for induction treatment with liposomal cytarabine/daunorubicin as per investigator judgement.
For R/R AML population:
- All Parts: Diagnosis of relapsed or refractory AML and suitable for treatment with IDAC as per investigator judgement.
- For Part 3 only: willingness and suitability to participate in DDI Cohort 1 or 2.
Exclusion Criteria:
- Prior exposure to MDM2 and MDM4 inhibitor (e.g. idasanutlin)
- Known symptomatic CNS leukemia not controlled by adequate therapy.
- Isolated extramedullary leukemia
- Subjects with prior malignancy (some exceptions apply)
- QTcF > 470 ms at screening
- Subjects who require treatment with moderate or strong CYP3A4 inducers within 14 days prior to starting study treatment or during the study
- Subjects who require use of herbal preparations/medications and dietary supplements within 7 days prior to first dose and during the study
- Subjects who require treatment with substrates of CYP3A4/5 with narrow therapeutic index (within 24 hours prior to during and 48 hours after HDM201 administration)
- Subjects who require treatment with moderate or strong CYP3A4 inhibitors within 48 hours prior to, during and 48 hours post HDM201 administration. (except for Part 3 DDI Cohort 1 and 2)
- Subject is pregnant or breastfeeding
- WOCBP unless using highly effective methods of contraception during study treatment and for an appropriate time period after last study treatment
- Sexually active males unless they use a condom during intercourse while taking study drug and for an appropriate time period after last study treatment
For Part 1 only:
- Subjects with a known favorable risk AML subtype at screening or subjects with FLT3 mutation
For Part 3 only:
- DDI Cohort 1: use of posaconazole (other than the planned dosing required by the protocol) within 7 days prior to start of the DDI investigation and for the duration of the DDI period
- DDI Cohort 2: use of midazolam (other than the planned dosing required by the protocol) within 2 days prior to start of the DDI investigation and for the duration of the DDI period
- DDI Cohort 1 and 2: subjects who have received, or are expected to receive moderate or strong inhibitors of CYP3A4 within 7 days prior to start of the DDI investigation, for the duration of the investigation, and 24 hours after last blood sample collection for PK assessment
Other protocol-defined inclusion/exclusion may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Part 1 - first line (1L) AML
1L acute myeloid leukemia (AML) subjects receiving HDM201 in various doses/schedules in combination with cytarabine/anthracyclines
|
2.5 mg and 10mg capsules, given orally
Other Names:
20mg or 1000 mg or other strengths as locally available given intravenously
Other Names:
20mg or other strength as locally available given intravenously
Other Names:
|
EXPERIMENTAL: Part 1 - relapsed/refractory (R/R) AML
R/R AML subjects receiving HDM201 in various doses/schedules in combination with cytarabine
|
2.5 mg and 10mg capsules, given orally
Other Names:
20mg or 1000 mg or other strengths as locally available given intravenously
Other Names:
|
EXPERIMENTAL: Part 2 - Expansion Cohort 1
1L de novo AML subjects without documented FLT3 mutation receiving HDM201 at the recommended dose of expansion (RDE) in combination with cytarabine/anthracyclines
|
2.5 mg and 10mg capsules, given orally
Other Names:
20mg or 1000 mg or other strengths as locally available given intravenously
Other Names:
20mg or other strength as locally available given intravenously
Other Names:
|
EXPERIMENTAL: Part 2 - Expansion Cohort 2
1L de novo AML subjects with documented FLT3 mutation status receiving HDM201 at RDE in combination with cytarabine/anthracyclines and midostaurin
|
2.5 mg and 10mg capsules, given orally
Other Names:
20mg or 1000 mg or other strengths as locally available given intravenously
Other Names:
20mg or other strength as locally available given intravenously
Other Names:
25mg capsules given orally
Other Names:
|
EXPERIMENTAL: Part 2 - Expansion Cohort 3
1L secondary AML subjects receiving HDM201 at RDE in combination with liposomal cytarabine/daunorubicin
|
2.5 mg and 10mg capsules, given orally
Other Names:
20mg or 1000 mg or other strengths as locally available given intravenously
Other Names:
100mg/44mg or other strength as locally available given intravenously
Other Names:
|
EXPERIMENTAL: Part 2 - Expansion Cohort 4
R/R AML subjects receiving HDM201 at RDE in combination with cytarabine
|
2.5 mg and 10mg capsules, given orally
Other Names:
20mg or 1000 mg or other strengths as locally available given intravenously
Other Names:
|
EXPERIMENTAL: Part 3 - DDI Cohort 1
R/R AML subjects receiving HDM201 at adjusted recommended Phase 3 dose (RP3D) determined in Part 2 in combination with cytarabine and posaconazole added in Cycle 1
|
2.5 mg and 10mg capsules, given orally
Other Names:
20mg or 1000 mg or other strengths as locally available given intravenously
Other Names:
100mg delayed release tablet or other strength as locally available given orally
Other Names:
|
EXPERIMENTAL: Part 3 - DDI Cohort 2
R/R AML subjects receiving HDM201 at RP3D in combination with cytarabine and midazolam
|
2.5 mg and 10mg capsules, given orally
Other Names:
20mg or 1000 mg or other strengths as locally available given intravenously
Other Names:
2mg/mL oral solution or in other strength as locally available
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 - Incidence of dose limiting toxicity (DLT)
Time Frame: first day of study treatment to 3 months after start of study treatment
|
number of DLTs by dose regimen of first line (1L) acute myeloid leukemia (AML) subjects during induction treatment; number of DLTs by dose regimen of relapsed/refractory (R/R) AML subjects during treatment
|
first day of study treatment to 3 months after start of study treatment
|
Part 1 - Time to DLT
Time Frame: first day of study treatment to 3 months after start of study treatment
|
time from first dose to onset of DLT by dose regimen of 1L AML and R/R AML subjects
|
first day of study treatment to 3 months after start of study treatment
|
Part 1 - Incidence and severity of Adverse Events (AEs)
Time Frame: first day of study treatment to 3 months after start of study treatment
|
number and grade of AEs by dose regimen of 1L AML and R/R AML subjects during DLT observation period
|
first day of study treatment to 3 months after start of study treatment
|
Part 2 - Incidence and severity of AEs/serious adverse events (SAEs)
Time Frame: first day of study treatment until 8.5 months after start of study treatment
|
number and grade of AEs/SAEs by expansion cohort
|
first day of study treatment until 8.5 months after start of study treatment
|
Part 2 - Percentage of participants with complete remission (CR)/CR with incomplete recovery (CRi) with adequate blood count recovery (ABCR)
Time Frame: first day of study treatment until 4.5 months after start of study treatment
|
Percentage of participants with CR/CRi with ABCR at the end of induction treatment for Expansion Cohort 1, and at the end of treatment for Expansion Cohort 4
|
first day of study treatment until 4.5 months after start of study treatment
|
Part 2 - Incidence and severity of abnormal laboratory values
Time Frame: first day of study treatment until 8.5 months after start of study treatment
|
number and grade of abnormal laboratory results by expansion cohort
|
first day of study treatment until 8.5 months after start of study treatment
|
Part 2 - Incidence and severity of abnormal electrocardiogram (ECG) results
Time Frame: first day of study treatment until 8.5 months after start of study treatment
|
number and severity of abnormal ECG results by expansion cohort
|
first day of study treatment until 8.5 months after start of study treatment
|
Part 2 - Incidence and severity of abnormal vital signs
Time Frame: first day of study treatment until 8.5 months after start of study treatment
|
number and severity of abnormal vital signs by expansion cohort
|
first day of study treatment until 8.5 months after start of study treatment
|
Part 3 - DDI Cohort 1 HDM201 Pharmacokinetics (PK) area under the curve (AUC)
Time Frame: first day of HDM201 dose to 10 days after start of HDM201
|
determine HDM201 AUC from time zero to the last measurable concentration sampling time (AUClast) in Cycle 1
|
first day of HDM201 dose to 10 days after start of HDM201
|
Part 3 - DDI Cohort 1 HDM201 PK maximum observed plasma concentration (Cmax)
Time Frame: first day of HDM201 dose to 10 days after start of HDM201
|
determine HDM201 Cmax in Cycle 1
|
first day of HDM201 dose to 10 days after start of HDM201
|
Part 3 - DDI Cohort 1 HDM201 PK average plasma concentration
Time Frame: first day of HDM201 dose to 10 days after start of HDM201
|
determine HDM201 average plasma concentration in Cycle 1
|
first day of HDM201 dose to 10 days after start of HDM201
|
Part 3 - DDI Cohort 1 HDM201 PK time of maximum observed plasma concentration (Tmax)
Time Frame: first day of HDM201 dose to 10 days after start of HDM201
|
determine HDM201 Tmax in Cycle 1
|
first day of HDM201 dose to 10 days after start of HDM201
|
Part 3 - DDI Cohort 2: midazolam PK AUC
Time Frame: first dose of midazolam (Day-2) to 8 days after start of study treatment (HDM201)
|
determine midazolam AUC last and AUC from time zero to infinity (inf)
|
first dose of midazolam (Day-2) to 8 days after start of study treatment (HDM201)
|
Part 3 - DDI Cohort 2: midazolam PK Cmax
Time Frame: first dose of midazolam (Day-2) to 8 days after start of study treatment (HDM201)
|
determine midazolam Cmax
|
first dose of midazolam (Day-2) to 8 days after start of study treatment (HDM201)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 +2: HDM201 PK AUC
Time Frame: first day of study treatment to 7.5 months after start of study treatment
|
determine HDM201 AUC by dose regimen in Part 1, and Expansion Cohort in Part 2
|
first day of study treatment to 7.5 months after start of study treatment
|
Part 1 +2: HDM201 PK Cmax
Time Frame: first day of study treatment to 7.5 months after start of study treatment
|
determine Cmax of HDM201 by dose regimen in Part 2, and Expansion Cohort in Part 2
|
first day of study treatment to 7.5 months after start of study treatment
|
Part 1 +2: HDM201 PK Tmax
Time Frame: first day of study treatment to 7.5 months after start of study treatment
|
determine Tmax of HDM201 by dose regimen in Part 2, and Expansion Cohort in Part 2
|
first day of study treatment to 7.5 months after start of study treatment
|
Part 1 - incidence of AEs/SAEs
Time Frame: first day of study treatment to 8.5 months after start of study treatment
|
number and grade of AEs/SAEs, by dose regimen for 1L AML and R/R AML subjects during study treatment + 30 days
|
first day of study treatment to 8.5 months after start of study treatment
|
Part 2 - all Expansion Cohorts: time to platelet recovery
Time Frame: first day of study treatment to 7.5 months after start of study treatment
|
determine time to platelet recovery by Expansion Cohort for each cycle
|
first day of study treatment to 7.5 months after start of study treatment
|
Part 2 - all Expansion Cohorts: time to neutrophil recovery
Time Frame: first day of study treatment to 7.5 months after start of study treatment
|
determine time to neutrophil recovery by Expansion Cohort for each cycle
|
first day of study treatment to 7.5 months after start of study treatment
|
Part 2 - all Expansion Cohorts: overall survival
Time Frame: first day of study treatment to 3 years after last patient is enrolled to Part 2
|
determine overall survival by Expansion Cohort
|
first day of study treatment to 3 years after last patient is enrolled to Part 2
|
Part 2 - all Expansion Cohorts: event-free survival
Time Frame: first day of study treatment to 3 years after last patient is enrolled to Part 2
|
determine event-free survival by Expansion Cohort
|
first day of study treatment to 3 years after last patient is enrolled to Part 2
|
Part 2 - all Expansion Cohorts: Percentage of subjects receiving Hematopoietic stem cell transplant (HSCT)
Time Frame: first day of study treatment to 3 years after last patient was enrolled to Part 2
|
percentage of subjects receiving HSCT after study treatment by Expansion Cohort.
|
first day of study treatment to 3 years after last patient was enrolled to Part 2
|
Part 2 - Expansion Cohorts 1 to 3: disease-free survival (DFS)
Time Frame: first day of study treatment to 3 years after last patient enrolled to Part 2
|
determine DFS by Expansion Cohort
|
first day of study treatment to 3 years after last patient enrolled to Part 2
|
Part 2 - Expansion Cohorts 1 to 3: cumulative incidence of relapse (CIR)
Time Frame: first day of study treatment to 3 years after last patient enrolled to Part 2
|
determine CIR by Expansion Cohort
|
first day of study treatment to 3 years after last patient enrolled to Part 2
|
Part 2 - Expansion Cohorts 2 and 3 - proportion of subjects with CR/CRi with ABCR
Time Frame: first day of study treatment to 7.5 months after start of study treatment
|
proportion of subjects achieving CR or CRi with ABCR by Expansion Cohort
|
first day of study treatment to 7.5 months after start of study treatment
|
Part 2 - Expansion Cohorts 1 and 2: proportion of subjects with minimal/measurable residual disease (MRD) negativity
Time Frame: first day of study treatment to 7.5 months after start of study treatment
|
proportion of subjects achieving MRD negativity by Expansion Cohort
|
first day of study treatment to 7.5 months after start of study treatment
|
Part 2 - expansion cohort 2: midostaurin PK AUC
Time Frame: first day of study treatment to 7.5 month after start of study treatment
|
determine midostaurin AUC
|
first day of study treatment to 7.5 month after start of study treatment
|
Part 2 - expansion cohort 2: midostaurin PK Cmax
Time Frame: first day of study treatment to 7.5 month after start of study treatment
|
determine midostaurin Cmax during induction and consolidation treatment
|
first day of study treatment to 7.5 month after start of study treatment
|
Part 2 - expansion cohort 2: midostaurin PK Tmax
Time Frame: first day of study treatment to 7.5 month after start of study treatment
|
determine midostaurin Tmax during induction and consolidation treatment
|
first day of study treatment to 7.5 month after start of study treatment
|
Part 1 - incidence of abnormal laboratory values
Time Frame: first day of study treatment to 8.5 months after start of study treatment
|
number of abnormal laboratory results by dose regimen for 1L AML and R/R AML subjects during study treatment + 30 days
|
first day of study treatment to 8.5 months after start of study treatment
|
Part 1 - incidence of abnormal ECG results
Time Frame: first day of study treatment to 8.5 months after start of study treatment
|
number of abnormal ECG results by dose regimen for 1L AML and R/R AML subjects during study treatment + 30 days
|
first day of study treatment to 8.5 months after start of study treatment
|
Part 1 - incidence of abnormal vital signs
Time Frame: first day of study treatment to 8.5 months after start of study treatment
|
number of abnormal vital signs by dose regimen for 1L AML and R/R AML subjects during study treatment + 30 days
|
first day of study treatment to 8.5 months after start of study treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- idarubicin
- HDM201
- minimal residual disease
- cytarabine
- dose escalation
- acute myeloid leukemia (AML)
- relapsed/refractory AML
- combination treatment
- midostaurin
- daunorubicin
- liposomal cytarabine/daunorubicin
- 1L newly diagnosed AML
- FLT3-mutation
- CR/CRi
- DDI with CYP3A4 inhibitors
- DDI with sensitive CYP3A4 substrate
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Central Nervous System Depressants
- Antiviral Agents
- Enzyme Inhibitors
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Protein Kinase Inhibitors
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antibiotics, Antineoplastic
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- 14-alpha Demethylase Inhibitors
- Trypanocidal Agents
- Midazolam
- Cytarabine
- Daunorubicin
- Idarubicin
- Posaconazole
- Midostaurin
Other Study ID Numbers
- CHDM201A2101
- 2018-003107-19 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Myeloid, Acute
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Kronos BioActive, not recruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States, Spain
Clinical Trials on HDM201
-
Novartis PharmaceuticalsTerminatedUveal MelanomaUnited States, Australia, France, Netherlands, Spain, Norway
-
Novartis PharmaceuticalsTerminatedAcute Myeloid Leukemia | Allogeneic Stem Cell TransplantationItaly, Germany, Spain
-
Novartis PharmaceuticalsCompletedLiposarcomaFrance, Taiwan, Germany, Spain, Canada, Singapore
-
Novartis PharmaceuticalsCompletedHepatic ImpairmentUnited States
-
Novartis PharmaceuticalsCompletedAdvanced Solid and Hematological TP53wt TumorsFrance, Netherlands, Spain, Germany, Singapore, Japan, Taiwan, United States
-
Centre Leon BerardNovartis; National Cancer Institute, FranceRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
Novartis PharmaceuticalsActive, not recruitingMyelofibrosisUnited Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
-
Novartis PharmaceuticalsActive, not recruitingAcute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)Spain, Singapore, Australia, Germany, Italy, Finland, United States
-
Centre Leon BerardNovartisCompletedColorectal Cancer | Metastatic Cancer | Advanced CancerFrance
-
University Hospital Inselspital, BerneTerminatedAML, AdultSwitzerland